Open Access
Subscription Access
Open Access
Subscription Access
New Approaches in the Treatment of Inflammatory Bowel Disease
Subscribe/Renew Journal
Inflammatory bowel disease (IBD) commonly refers to ulcerative colitis (UC) and Crohn disease (CD), which are chronic inflammatory diseases of the GI tract of unknown etiology. This inflammatory response is most likely made possible by defects in both the mucosal immune system and the barrier function of the intestinal epithelium. Many conventional treatments are used to inhibit inflammation and suppress the immunological response like 5-amino salicylic acid, Corticosteroids, antibiotics etc. Recently biological therapy involving specific molecular players which are specialized proteins interfering with the body's inflammatory response are targeted for treatment of IBD Promising targets include tumor necrosis factor TNF-alpha, interleukins, adhesion molecules, colony-stimulating factors, and others. Elevation of cAMP by PDE4 inhibition and selective COX-2 inhibition is a new option to treat inflammatory bowel disease.
Keywords
Inflammatory Bowel Disease, TNF-Alpha.
Subscription
Login to verify subscription
User
Font Size
Information
- Sartor RB. (1995) Current concepts of the etiology and pathogenesis of Ulcerative colitis and Crohn's disease. Gastroenterol Clin North Am.1995, 24: 475-485.
- Giorgos Bamias, MD; Mark R. Nyce, MD; Sarah A. De La Rue, PhD; and Fabio Cominelli, MD, PhD. (20 December 2005); Volume 143 Issue 12|Pages 895-904.
- Loftus EV Jr, Silverstein MD, Sandborn WJ, et al. Ulcerative colitis in Olmsted County, Minnesota, 1940-1993: incidence, prevalence, and survival. Gut. 2000, 46:336-343.
- Sandler RS. Epidemiology of inflammation bowel disease. In: Targan SR, Shanahan F, eds.(1994). Inflammatory Bowel Disease: From Bench to Bedside. Baltimore: Williams and Wilkins, 1994, 330-335.
- Moum B, Vatn MH, Ekbom A, et al. Incidence of Crohn's disease in four counties in southeastern Norway, 1990-93. A prospective population-based study. The Inflammatory Bowel South-Eastern Norway (IBSEN) Study Group of Gastroenterologists. Scand J Gastroenterol. 1996, 31:355-361.
- Niv Y, Abuksis G, Fraser GM.(2000). Epidemiology of ulcerative colitis in Israel: a survey of Israeli kibbutz settlements. Am J Gastroenterol. 2000, 95:693-698.
- Sandborn WJ, Tremaine WJ, Offord KP, et al. Transdermal nicotine for mildly to moderately active ulcerative colitis: a randomized, double-blind, placebo-controlled trial. Ann Intern Med. 1997, 126:364-371.
- Loftus EV Jr, Silverstein MD, Sandborn WJ, et al. Ulcerative colitis in Olmsted County, Minnesota, 1940-1993: incidence, prevalence, and survival. Gut. 2000, 46:336-343.
- Evans JM, McMahon AD, Murray FE, McDevitt DG, MacDonald TM. Nonsteroidal anti-inflammatory drugs are associated with emergency admission to hospital for colitis due to inflammatory bowel disease. Gut. 1997, 40:619-622.
- Lindberg E, Tysk C, Andersson K, Jarnerot G. Smoking and inflammatory bowel disease: a case control study. Gut. 1988, 29:352-357.
- Sandborn WJ, Tremaine WJ, Offord KP, et al. Transdermal nicotine for mildly to moderately active ulcerative colitis: a randomized, double-blind, placebo-controlled trial. Ann Intern Med. 1997, 126:364-371.
- Kathleen A. Head, ND and Julie S. Jurenka, MT (ASCP), Alternative Medicine Review Inflammatory bowel disease part-I: ulcerative colitis-pahophysiology and conventional and alternative treatment options. 2003, Volume 8, number 3, p.247-283.
- Barbara A. Hendrickson, Ranjana Gokhale, and Judy H. Cho, Clinical Aspects and Pathophysiology of Inflammatory Bowel Disease. Clinical Microbiology Reviews, January 2002, Vol. 15, No. 1 p. 79-94.
- Lashner BA. Recommendations for colorectal cancer screening in ulcerative colitis: a review of research from a single university-based surveillance program. Am J Gastroenterol. 1992, 87:168-75.
- Lindberg E, Tysk C, Andersson K, Jarnerot G. Smoking and inflammatory bowel disease: a case control study. Gut. 1988, 29:352-357.
- Sandborn WJ, Tremaine WJ, Offord KP, et al. Transdermal nicotine for mildly to moderately active ulcerative colitis: a randomized, double-blind, placebo-controlled trial. Ann Intern Med. 1997, 126:364-371.
- Kathleen A. Head, ND and Julie S. Jurenka, MT (ASCP), Alternative Medicine Review Inflammatory bowel disease part- I: ulcerative colitis-pahophysiology and conventional and alternative treatment options. 2003, Volume 8, number 3, p. 247-283.
- Lindberg E, Tysk C, Andersson K, Jarnerot G. Smoking and inflammatory bowel disease: a case control study. Gut. 1998, 29:352-357.
- Sandborn WJ, Tremaine WJ, Offord KP, et al. Transdermal nicotine for mildly to moderately active ulcerative colitis: a randomized, double-blind, placebo-controlled trial. Ann Intern Med. 1997, 126:364-371.
- Kathleen A. Head, ND and Julie S. Jurenka, MT (ASCP), Alternative Medicine Review Inflammatory bowel disease part- I: ulcerative colitis- pahophysiology and conventional and alternative treatment options. 2003, Volume 8, number 3, p. 247-283.
- Barbara A. Hendrickson, Ranjana Gokhale, and Judy H. Cho, Clinical Aspects and Pathophysiology of Inflammatory Bowel Disease. Clinical Microbiology Reviews, Jan 2002, Vol. 15, No. 1 p. 79-94.
- Lashner BA. Recommendations for colorectal cancer screening in ulcerative colitis: a review of research from a single university-based surveillance program. Am J Gastroenterol. 1992, 87:168-75.
- Kwon JH, Keates S, Bassani L, Mayer LF, Keates AC. Colonic epithelial cells are a major site of macrophage inflammatory protein 3alpha (MIP-3alpha) production in normal colon and inflammatory bowel disease. Gut. 2002, 51:818-26. [PMID:12427784].
- Miner PB.Clinical features, course, laboratory findings, and complications in ulcerative colitis. In: Kirsner JB, ed. Inflammatory Bowel Disease. 5th ed. Philadelphia, Pa: WB Saunders Co; 2000, 299-304.
Abstract Views: 235
PDF Views: 4